Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belimumab + interleukin-2
- Development stage
- Unknown
- Lead developer
- Peking University People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Belimumab + interleukin-2 is an investigational combination therapy being evaluated by Peking University People's Hospital for the treatment of systemic lupus erythematosus (SLE). Belimumab is a human monoclonal antibody that targets and inhibits B-lymphocyte stimulator (BLyS), also known as B-cell activating factor (BAFF), which is essential for the survival and differentiation of B cells into autoantibody-producing plasma cells. Low-dose interleukin-2 (IL-2) is used to selectively stimulate the expansion and function of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs), which are typically deficient or dysfunctional in SLE patients. This dual approach aims to synergistically restore immune homeostasis by suppressing pathogenic B-cell activity while simultaneously enhancing immunoregulation through Treg expansion.
- Other names
- low-dose interleukin-2 and belimumab combination
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)BAFF (Tumor necrosis factor ligand superfamily member 13B)
Beyond the preview
Go deeper on belimumab + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belimumab + interleukin-2.